A phase II study, that included both PV and ET patients, reported that 69% of ET patients and 100% of PV patients had a response (either PR or CR) to PEG-IFN-α-2b, though this was a small study that included 13 ET patients and only 4 PV patients [59]. The gene discussed is IFNA2; the disease is essential thrombocythemia.